Mr Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Since September 2023 Mr Sullivan has been the CFO of Convergent Therapeutics, Inc. He is the chairperson of Risk Committee.
